OnCore BioPharma

Tekmira changes name to Arbutus Biopharma, a hepatitis B solutions company

Wednesday, July 22, 2015

Tekmira Pharmaceuticals, headquartered in Vancouver, Canada, plans to change its corporate name to Arbutus Biopharma, a therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), to be effective on or before Aug. 3. The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the singular goal of delivering a cure for chronic HBV. The combined entity currently fields a large portfolio of HBV product candidates in the industry.

[Read More]

Tekmira Pharmaceuticals, OnCore Biopharma to merge

Wednesday, January 14, 2015

Tekmira Pharmaceuticals, based in Vancouver, a developer of RNA interference (RNAi) therapeutics, and OnCore Biopharma, a Doylestown, Pa.-based biopharmaceutical company dedicated to discovering, developing and commercializing an all-oral cure for patients suffering from chronic hepatitis B virus (HBV) infection, have agreed to merge to create a new global HBV company focused on developing a curative regimen for hepatitis B patients by combining multiple therapeutic approaches.

[Read More]

NeuroVive Pharmaceutical, Oncore Biopharma ink $150M agreement

Wednesday, September 10, 2014

NeuroVive Pharmaceutical, a Swedish mitochondrial medicine company, has signed an exclusive global out-licensing agreement with the Pennsylvania-based OnCore BioPharma for the development and commercialization of NeuroVive’s drug candidate NVP018 for oral treatment of chronic hepatitis B virus (HBV) infection. The agreement could give NeuroVive a total of $150 million in conditional milestone payments, plus royalties on future drug sales.

[Read More]